A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)

Running, not enrolling

Conditions studied: Age Related Macular Degeneration

In brief

This study proposes to use a new instrument (AO-OCT/AF: adaptive optics - optical coherence tomography/autofluorescence) combined with a data processing method to image the retinal pigment epithelium (RPE) of the eye in normal subjects and in subjects with age-related macular degeneration. (AMD). While currently there is no cure, with early diagnosis, vision loss can be slowed. The technology being developed for this project will be the first imaging modality that can provide both structural and molecular information about the retina in vivo and in 3D.

Key facts

Study ID

NCT03963817

Run by

Icahn School of Medicine at Mount Sinai

People needed

50

Starts

2023-09-06

Expected to finish

2027-12-01

Last updated by the study team

2026-02-24

Who can join

Age: 60 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients must be aged 60 and over and pseudophakic, with clear posterior capsule and dilation to 6mm.
• Patients must be diagnosed early/intermediate AMD in at least one eye (the study eye) with soft drusen or reticular pseudodrusen in the macula.

You may not qualify if…

• Retinopathy other than AMD.
• Inability to give informed consent
• Bilateral advanced AMD
• Allergy to dilation eye drops

Where it is running

• New York Eye and Ear Infirmary of Mount Sinai — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.